Almotriptan
Almotriptan
CLINICAL USE
Acute relief of migraine
DOSE IN NORMAL RENAL FUNCTION
12.5 mg repeated after 2 hours if migraine
recurs (do not take 2nd dose for the same
attack)
Maximum 25 mg in 24 hours
PHARMACOKINETICS
Molecular weight :
469.6 (as malate)
%Protein binding :
35
%Excreted unchanged in urine :
40–50
Volume of distribution (L/kg) :
195 litres
half-life – normal/ESRD (hrs) :
3.5/7
DOSE IN RENAL IMPAIRMENT
GFR (mL/MIN)
30–50 Dose as in normal renal function
10–30 6.25 mg; maximum daily dose
12.5 mg. Use with caution
<10 :
6.25 mg; maximum daily dose
12.5 mg. Use with caution
DOSE IN PATIENTS UNDERGOING RENAL REPLACEMENT THERAPIES
CAPD :
Unknown dialysability. Dose as in
GFR <10 mL/min
HD :
Likely dialysability. Dose as in
GFR <10 mL/min
HDF/high flux :
Likely dialysability. Dose as in
GFR <10 mL/min
CAV/VVHD :
Unknown dialysability. Dose as in
GFR=10–30 mL/min
IMPORTANT DRUG INTERACTIONS
Potentially hazardous interactions with other drugs
Antidepressants: possibly increased
serotonergic effects with duloxetine;
increased serotonergic effects with St
John’s wort – avoid concomitant use
Antifungals: concentration increased by
ketoconazole (increased risk of toxicity)
Ergot alkaloids: increased risk of
vasospasm
ADMINISTRATION
Reconstition
–
Route
Oral
Rate of Administration
–
Comments
–
See how to identify renal failure stages according to GFR calculation
See how to diagnose irreversible renal disease
Home
